𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I study of intravenous bromodeoxyuridine used concomitantly with radiation therapy in patients with primary malignant brain tumors

✍ Scribed by Surasak Phuphanich; Ellen M. Levin; Victor A. Levin

Publisher
Elsevier Science
Year
1984
Tongue
English
Weight
463 KB
Volume
10
Category
Article
ISSN
0360-3016

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase I study of cranial radiation the
A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors
✍ Liu, Li ;Vapiwala, Neha ;Munoz, Louis K. ;Winick, Naomi J. ;Weitman, Steven ;Str πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 59 KB

## Background: The prognosis of children with high-grade astrocytomas of the central nervous system is grim and has not been substantially improved by conventional chemoradiotherapy. we performed a multi-institutional phase i study to determine the toxicities and tolerance of concurrent external be

Phase I study of fotemustine in pediatri
Phase I study of fotemustine in pediatric patients with refractory brain tumors
✍ Darren R. Hargrave; Eric Bouffet; Janet Gammon; Nauman Tariq; Ron M. Grant; Sylv πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 184 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Fotemustine is a nitrosourea with theoretic and preclinical advantages over the original analogs, carmustine and lomustine, in the treatment of brain tumors. This is the first pediatric Phase I study of fotemustine. ## METHODS Patients younger than 21 with recurrent/res

Primary central nervous system lymphoma:
Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy
✍ Bouthaina S. Dabaja; Peter McLaughlin; Chul S. Ha; Barbara Pro; Christina A. Mey πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 95 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The current study was performed to determine the maximum tolerated dose (MTD), toxicity, and outcome of infusional 5 bromo‐2'‐deoxyuridine (bromodeoxyuridine; BUdR) given with accelerated fractionation whole brain radiation therapy (WBRT) after chemotherapy for the treatm